Archana Gautam, MD
Cardiovascular Disease · Norman, OKNPI 1023158482
Payments from drug & device makers
Across 298 payments — averaging $71.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$9K
- Pfizer$3K
- Penumbra, Inc.$2K
- Abbott$2K
- Baylis Medical Company Inc$867
- Abiomed$686
- plus $4K from 36 others
What the payments were for
- Consulting fees$2,40011%
- Grants$1,5307%
- Travel & lodging$8,76641%
- Food & beverage$8,61740%
- Education$380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$2,400
- Indigo System$2,125
- COREVALVE EVOLUT R$1,812
- CoreValve Evolut$1,363
- Xience V coronary stent system$1,178
- 3F$1,123
- VersaCross Access Solution$867
- Visia AF$783
- Attain$582
- Impella$417
- Amplia MRI$402
- Xience Sierra Coronary Stent System$278
- Micra$269
- Watchman$244
- QDOT MICRO Catheter$192
- AURORA EV-ICD MRI SURESCAN$107
- WATCHMAN Access System$107
- Barostim Neo System$104
How this compares
$21,351 in reported general payments places this provider in the 85th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 502 | $621,235 |
| EntrestoSacubitril/Valsartan | 147 | $215,867 |
| FarxigaDapagliflozin Propanediol | 156 | $196,639 |
| XareltoRivaroxaban | 86 | $87,250 |
| BrilintaTicagrelor | 77 | $68,819 |
| JardianceEmpagliflozin | 43 | $48,629 |
| Repatha SyringeEvolocumab | 51 | $44,900 |
| Repatha SureclickEvolocumab | 28 | $24,877 |
| Metoprolol Succinate | 728 | $11,259 |
| Rosuvastatin Calcium | 514 | $9,158 |
| Valsartan | 200 | $6,715 |
| Nebivolol Hcl | 66 | $6,239 |
| Atorvastatin Calcium | 408 | $5,380 |
| ClopidogrelClopidogrel Bisulfate | 343 | $5,336 |
| Carvedilol | 310 | $4,034 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $2,604 | $621,235502 claims |
| AstraZenecaFarxiga, Brilinta | $30 | $265,459233 claims |
| NovartisEntresto | $538 | $215,867147 claims |
| Johnson & JohnsonXarelto | $249 | $87,25086 claims |
| Boehringer IngelheimJardiance | $22 | $48,62943 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Norman
- Muhammad SalimNorman$8K
- Michael SellersNorman$6K
- Jeffrey CrookNorman$6K
- Norman AyersNorman$6K
- Anderson MehrleBartlesville$1.6M
- Eric AuerbachTulsa$636K
- Nicholas HannaTulsa$446K
- Frank GaffneyTulsa$243K
- Stavros StavrakisOklahoma City$174K
- Ravi KodeTulsa$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.